Newark, DE – March 15, 2010. Accugenix announces a new strategic partnership with Agenolab GmbH
& Co.KG to provide pharmaceutical, biotechnology, medical device and other manufacturing industries
with local access and convenience to the Company’s expertise in microbial identification services. For
over 20 years, Accugenix has tested more microorganisms than any other company or service laboratory
in world, which has allowed the company to develop and refine a validated proprietary organism library
and method of interpretation unrivaled in the industry. Now, European organizations can directly
benefit from these world-class capabilities with the convenience of working with a local laboratory.
Agenolab provides both genotypic and proteotypic sample analysis in their Stuttgart facility in Germany,
and is electronically linked to Accugenix’s Newark, Delaware facility in the US where data analysis,
interpretation and result reporting is conducted.
“The presence of a European lab enables our customers to benefit from the same level of service in
accuracy, reliability and convenience that our US customers have enjoyed for years”, according to Doug
Smith, Chief Executive Officer of Accugenix. “We were delighted to find a partner so appropriately
suited to expand our presence in Europe and uphold our commitment to the highest of cGMP and EU
GMP.”
Agenolab GmbH & Co.KG is an innovative biotechnology & life science laboratory. Founded in 2007,
Agenolab is continuously growing and expanding its collaborations, implementing state-of-the art
technologies, using the most advanced equipment and maintaining a continuously trained, highly
motivated staff and “Gold Standard” services.
About Accugenix
For over 20 years, Accugenix has been the world’s leading FDA-registered, cGMP service laboratory for
microbial identification and characterization. More than 1000 facilities around the world rely on the
company’s expertise to meet their microbial identification needs.
